DRUG FAMILY NAMES CNS / NEUROMUSCULAR INFECTIOUS DISEASE FAMILY NAME TYPE OF DRUG FAMILY NAME TYPE OF DRUG
Carbachol
Imipenem
Atropine
Meropenem Scopolamine
Ciprofloxacin -stigmine
Neostigmine -floxacin
Levofloxacin
Atracurium
Ketoconazole -conazole -curonium
Mivacurium
Fluconazole
Pancuronium “azole” drugs
Itraconazole
Halothane
Chloroquine
Lidocaine
Primaquine
Diazepam
Acyclovir
Lorazepam
Ganciclovir
Phenobarbital
Valacyclovir
Thiopental
Antiviral (Influenza)
Zanamivir Naloxone Nal…-one Naltrexone
Oseltamivir
Chlorpromazine
Antiviral (AIDS/HIV)
Indinavir
Thioridazine
Ritonavir
Clozapine
Risperidone
Tolcapone GI SYSTEM
Entacapone FAMILY NAME TYPE OF DRUG CARDIOVASCULAR AND RENAL
Cimetidine
Ranitidine FAMILY NAME TYPE OF DRUG -prazole
Omeprazole -glitazone
Pioglitazone
Carvedilol
Nifedipine -gliptin
Sitagliptin
Prazosin
Doxazosin
Ondansetron Granisetron
Terazosin
Captopril
Losartan MISCELLANEOUS
Amiodarone
HMG CoA Reductase Inhibitor Lovastatin FAMILY NAME TYPE OF DRUG
Zafirlukast -zolamide
Acetazolamide -lukasts
Dorzolamide
Montelukast
Furosemide
Celecoxib
Enoxaparin
Misoprostol
Alprostadil
Bivalirudin
Alendronate
Lepirudin -dronate
Pamidronate ONCOLOGY
Sildenifil
Amrinone FAMILY NAME TYPE OF DRUG -triptan
Sumatriptan Vincristine Vinblastine Doxorubicin -rubicin
Daunorubicin Rituximab
Trastuzumab
Imatinib
Copyright 2013 Thunderpath Media Inc Baronerocks.com
MARZO 2010 DAL N. 289 AL N. 546 POSIZIONI ORGANIZZATIVE - CONFERIMENTO INCARICO DI FUNZIONE SPESA FARMACEUTICA CONVENZIONATA MESE DI GENNAIO 2010 ASSISTENZA RIABILITATIVA LIQUIDAZIONE FATTURE ISTITUTO OSPEDALIERO DI SOSPIRO RELATIVE AL RICOVERO DELL'ASSISTITO C.V. PERIODO : NOVEMBRE E DICEMBRE 2009 ASSISTENZA DIALIZZATI ,RIMBORSO SPESE VIAGGI MESI DI NOVEMBRE E DICEMBRE 2009 PUIBBLI
These brief clinical guidelines and their supporting base of research evidence is intended to assist in the management of acute back pain. It presents a synthesis of up-to-date international evidence and makes recommendations on case management. Recommendations and evidence relate primarily to the first six weeks of an episode, when management decisions may be required in a changing clinical
DRUG FAMILY NAMES